was supported in part by US National Institutes of Health grant T32 GM007250
Adverse Effects of GLP-1 Receptor Agonists Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice
Safety Monitoring: Who Needs Enhanced Lab Surveillance Patients with pre-existing kidney disease, liver cirrhosis, thyroid nodules, or personal/family history of medullary thyroid cancer require more frequent biomarker checks and may not be candidates for GLP-1 therapy
For outcomes that included 10 or more studies, publication bias was assessed via Eggers test, and regression analyses were performed on the basis of patient age, weight, BMI, and duration of diabetes to explore potential heterogeneity
Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum
Contains: 4 x 0.5 mL Single-dose Prefilled Syringes Push to open Guideline Central and select third party use cookies on this website to enhance the user experience